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The purpose of this study is to determine features of uterine leiomyoma on Magnetic 
Resonance Imaging (MRI) that identify predictors of response to Uterine Arterial 
Embolization (UAE). MRI images were obtained before and after UAE in 35 women. 
These images were analyzed for uterine and fibroid size changes along with fibroid border 
characteristics and location for a total of 73 fibroids. Fibroids were classified as either 
smooth or lobulated based on border appearance on MR imaging to determine any 
differences in mean fibroid volume reduction post-embolization. The mean decrease in 
fibroid volume from pre-embolization to post-embolization was 48.1% ± 28.6 % (SD) (P < 
0.001). No statistical difference was detected in the mean volume reduction between 
lobulated and smooth fibroids, 40.6% ± 23.1% (SD) and 50.9% ± 30.2% (SD) respectively, 
with a confidence interval [-25.1, 4.6, SEM 7.5, Df 71], single factor ANOVA 
(F[1,71]=1.88, Fcrit=3.98, p=0.17). However, some difference was detected in the failure 
rate of lobulated versus smooth fibroids to embolization, 5% and 9.4% respectively, 
ANOVA (F [1, 71]= 0.37, Fcrit= 3.98, p > 0.1), albeit at low statistical power. Also no 
difference was detected in mean fibroid volume reduction between intramural, submucosal, 
and subserosal fibroids. Thus, we introduced a novel characteristic by which to classify 
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C h a p t e r  1  
INTRODUCTION 
Background / Incidence 
Uterine leiomyomas, also known as fibroids, are benign tumors arising from the smooth 
muscle of the uterus and contain various amounts of interstitial fibrotic tissue. Although the 
genesis of such fibroids is uncertain, it is thought that a multi-factorial process involving 
hormone dysregulation along with genetic factors may play a large role in the formation of 
uterine fibroids. Gonadal steroids are thought to play a large role in the growth of fibroids, 
however the formation of fibroids is not necessarily linked to these hormones. 
While the true incidence of fibroids is unknown due to the high prevalence of 
asymptomatic patients, the reported incidence is generally between 20% and 40% with a 
much higher incidence of nearly 50% in women of African-American heritage. In African 
American women, the estimated cumulative incidence by age 50 is greater than 80%, while 
in Caucasian women the estimated cumulative incidence by age 50 is around 70% (1). 
Most women with symptomatic fibroids are between 30 and 40, with few fibroids 
described in adolescent women. 
Risk Factors 
Women of African American descent are two to three times as likely to develop fibroids as 
Caucasian women. In addition to increased incidence, African American women are likely 
to be younger at the time of presentation with greater severity of disease related to higher 
uterine volumes and increased bleeding (2). Other risk factors for fibroid formation include 
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nuliparity (3, 4) and family history of fibroids (5). Factors that have been shown to reduce 
risk for fibroid formation include parity, and smoking, through an unknown mechanism 
(3). 
Clinical Presentation 
As mentioned previously, a large number of women with uterine fibroids are 
asymptomatic. Fibroids that are symptomatic can manifest with a variety of symptoms. 
While the clinical presentation of fibroids differs in each woman, the most common 
presenting symptom is that of menorrhagia or metrorrhagia. Symptoms are typically related 
to the size, location, and direction of growth of the fibroids, and fall into three broad 
categories, uterine bleeding, pelvic pressure, and disturbances in reproduction. As 
mentioned uterine bleeding is typically menorrhagia or metrorrhagia and can result in other 
secondary symptoms related to anemia, such as fatigue or depression among others. 
Typically increased bleeding occurs with submucosal fibroids due to an increased 
endometrial surface and a resultant larger bleeding area (6). Symptoms related to pelvic 
pressure vary based on location, with fibroids in the anterior lower uterine segment 
typically responsible for symptoms of urinary frequency from compression of the bladder. 
Posterior fibroids may be responsible for symptoms of constipation due to pressure on the 
rectum. Pain is also a common symptom related to increased pelvic pressure and can often 
be associated with a low grade fever, tenderness, and elevated white blood cell count. 
Fibroids may also be responsible for increased complications during pregnancy. Women 
with fibroids during pregnancy may experience an increased risk of abruptio placentae, 
premature labor, miscarriage, and breech presentation at birth (7, 8). 
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Medical Management 
Medical therapy is not the mainstay of treatment and is primarily used for relief of 
symptoms or as a bridging treatment prior to surgery. Currently several pharmacotherapies 
exist which may provide temporary relief of symptoms. However, discontinuation of 
medical therapy often results in a rapid return of symptoms. The current mainstay of 
medical treatment involves the use of gonadotropin releasing hormone agonists as a 
hormone suppressive therapy. The gonadotropin releasing hormone agonists act to 
reproduce a pharmacological state of menopause by initially increasing the release of 
gonadotropins followed by a downregulation leading to a hypogonadal state (9). In most 
cases, treatment with gonadotropin releasing hormone agonists results in a reduction in 
uterine bleeding and a return to baseline of hematologic labs. Treatment also reduces 
fibroid size in most cases and can effectively manage symptoms of pelvic discomfort (10). 
Common side effects with gonadotropin releasing hormone agonists include osteoporosis, 
hot flashes, vaginal dryness, and transient frontal headaches (11). Reports of decreased 
bone density have also been reported leading to osteoporosis (10). 
While the use of gonadotropin releasing hormone agonists do not constitute an effective 
primary therapy, their use prior to surgery as an adjunct therapy has considerable benefit in 
certain cases (11). In women undergoing myomectomy for fibroids, the use of 
gonadotropin release hormone agonists may permit a smaller incision, or for women 
undergoing hysterectomy, may allow vaginal hysterectomy due to a reduction in uterine 
and fibroid size. In women with considerable blood loss secondary to fibroids, the use of 
gonadotropin releasing hormone agonist may also allow for a return in hematocrit over 
time alleviating the need for blood transfusion (12). 
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Surgical Management 
As mentioned, surgery is the mainstay of treatment for uterine fibroids. Surgery is indicated 
in cases of symptomatic uterine fibroids not adequately controlled by more conservative 
treatment or in cases where a high suspicion of malignancy exists. Other indications for 
surgical management include growth of uterine fibroids following menopause, infertility 
related to tubal obstruction, or recurrent pregnancy loss (13). Several options exist for 
surgical management including total hysterectomy, myomectomy, and several newer 
procedures, such as uterine artery occlusion, and uterine artery embolization. 
Hysterectomy 
Currently in the United States more than 600,000 hysterectomies are performed per year 
(14). Nearly a quarter to a third of the hysterectomies performed in the United States are 
performed for symptomatic uterine fibroids (15). The advantage of classic hysterectomy 
includes relief from symptomatic uterine fibroids, as well as eliminating the chance of 
recurrence. A recent study following 1,299 women found that over 90% of the women 
noticed improved quality of life, decreased symptoms, and decreased depression two years 
after hysterectomy (16). Hysterectomy is also indicated over other surgical procedures 
when a high suspicion of malignancy exists or in patients with extensive fibroids not 
amenable to myomectomy. In the absence of these factors, issues concerning uterine 
conservation and future child-bearing should be addressed when considering between the 
available options. 
While the overall mortality rate with hysterectomy is quite low, this procedure is not 
without complications. Complications that are seen most often include incontinence, 
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vaginal vault prolapse, and risk of premature ovarian failure (17). Incontinence secondary 
to urinary tract injuries during surgery often occur most commonly in cases where uterine 
fibroids extend into the broad ligament, compress the bladder, or extend deep into the 
pelvis (13). 
Myomectomy 
Myomectomy is a surgical alternative to hysterectomy and allows for the preservation of 
the uterus along with the possibility of future pregnancies. In cases involving a solitary 
pedunculated fibroid, myomectomy is also the preferred surgical treatment. Although 
myomectomy is an effective therapy for menorrhagia and pelvic pressure, the disadvantage 
of this procedure is the significant risk that fibroids will re-occur. While hysterectomy 
eliminates the reoccurrence of fibroids, according to a recent meta-analysis study, fibroids 
may reoccur in nearly 20-50% of cases 5 years after myomectomy (18). 
Hysteroscopic Myomectomy 
Submucosal fibroids can be removed by a procedure known as hysteroscopic 
myomectomy. This procedure utilizes the submucosal location of fibroids to enter the 
cervix without an incision using a specialized scope that can cut and coagulate tissue from 
within the cavity. Compared to abdominal myomectomy, hysteroscopic myomectomy 
offers several advantages including the use of local anesthetic versus general anesthesia. 
Hysteroscopic myomectomy is also an outpatient procedure with a short recovery period. 
As described in a large prospective study of 156 women followed over 9 months after 
hysteroscopic myomectomy, fewer than 16% of women underwent a subsequent procedure 
for recurrent menorrhagia (19). For women considering pregnancy, hysteroscopic 
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myomectomy offers excellent fertility rates with a very low complication rate. In one study 
of 23 patients with associated infertility, pregnancy was achieved in eight cases following 
hysterscopic myomectomy (20). 
Laparoscopic Uterine Artery Occlusion 
Uterine artery occlusion is performed as a laparoscopic procedure in which the uterine 
arteries supplying the dominant fibroids are occluded. The advantage of this procedure 
compared to uterine artery embolization is that this approach allows for thorough and direct 
examination of the pelvis and avoids the use of foreign material such as embolization 
agents into the body. However a disadvantage of this procedure over uterine artery 
embolization is that it is still a surgical approach requiring general anesthesia. 
Uterine Artery Embolization 
Uterine artery embolization (UAE) was first reported as a successful treatment for life-
threatening gynecologic bleeding in 1979 (21, 22). Since this initial successful intervention, 
UAE has been reported as a successful procedure in the control of bleeding from a variety 
of different sources including tumors and traumatic pelvic injuries (23-25). The first use of 
UAE for symptomatic uterine fibroids was reported in 1994 (26) and given the relative lack 
of complications and relatively high success rates reported in initial cases, research into 
uterine fibroid embolization (UFE) as a possible treatment for symptomatic uterine fibroids 
continued (27-29). 
Indication for Embolization 
Compared to hysterectomy and medical treatment, uterine fibroid embolization is a 
relatively new procedure. To date, no absolute criteria exist for the indication to perform 
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UFE. From the literature the most common indications to perform UFE include contra-
indications to surgery and recurrent fibroids following alternative therapies such as 
myomectomy (30). In the management of uterine fibroids prior to considering UFE, a 
thorough gynecological workup must be performed in order to consider relevant 
differential diagnoses such as endometrial polyps, leiomyosarcoma, focal contractions of 
the myometrium, and extrauterine findings (e.g., ovarian tumors), all of which are absolute 
contraindications for UFE. In addition to a thorough gynecological workup, further 
imaging studies should be obtained prior to performing UFE to provide more detailed 
information regarding type, size, and exact number of fibroids. MRI is the preferred 
imaging modality allowing a detailed overview of the pelvic anatomy along with the ability 
to differentiate carcinomas of the endometrium, adenomyosis, and different types of 
fibroids (31, 32). 
It is unclear whether adenomyosis represents an absolute contra-indication to UFE, several 
reports describe circumstances where patients with adenomyosis do not improve 
symptomatically after UFE (33, 34). However, a single study in the literature reports 
improvement of clinical symptoms in adenomyosis after UFE (35). Other relative contra-
indications for UFE include non-growing fibroids in menopausal women or in 
postmenopausal women with atypical bleeding, along with pedunculated or very large 
fibroids extending above the level of the umbilicus (30). Absolute contra-indications for 
UFE in addition to those listed above include fibroids with a very thin pedicle, infection of 
the genital tract, and contra-indications to contrast dyes. 
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Technique of Embolization 
Uterine fibroid embolization (UFE) involves the placement of a catheter and the injection 
of embolization agent into the dominant artery or arteries that supply the uterine fibroids. 
Typically access is obtained through a femoral access route, then traversing the internal 
iliac artery to the uterine artery. Most fibroids due to the dual supply of the uterus from 
both uterine arteries are also supplied by both uterine arteries, necessitating embolization of 
both uterine arteries (36, 37). However, arteriography before embolization is necessary to 
exclude any additional supplying arteries or aberrant arterial malformations.  
In general UFE takes advantage of the fact that uterine fibroids are typically supplied by 
high flow arterial branches of the uterine arteries. This is in stark contrast to the normal 
myometrium, which tends to be supplied by low flow arterial branches of the uterine 
arteries. The difference in flow rates of the arteries supplying the fibroids versus the normal 
myometrium allows placement of the catheter delivering the embolization agent relatively 
proximal in the uterine artery with delivery of the embolization agent somewhat selectively 
to the branches supplying the fibroid or fibroids given their high flow state. 
The choice of embolization agent is highly user dependent with choices ranging from 
polyvinyl alcohol particles, gelfoam, and stainless steel coils, to tris-acryl gelatin 
microspheres. To date there exists no consensus on the most effective embolization agent, 
however a recent study noted that the use of spherical polyvinyl alcohol particles led to a 
particularly high rate of failed fibroid tumor infarction (38). Additionally, no consensus 
exists on the ideal size of embolizing particles, with reports suggesting success with 
particle sizes ranging from 150-500 μm to 500-710 μm (39-41). Some reports have 
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suggested that smaller embolization particles may result in a greater overall decrease in size 
of fibroids, however an increase in the rate of complications notably ovarian and cervical 
ischemia (40). 
Results of Embolization 
Following uterine fibroid embolization, technical success rates vary from 85% to 100% in 
most reported studies (42-44). Technical success is characterized by occlusion or marked 
reduction in the blood flow of both uterine arteries, and not by reduction in size of fibroids, 
or reduction of symptoms. Clinical success on the other hand involves parameters that 
include the reduction in size of fibroids, reduction of patient symptoms, and patient 
satisfaction. The range of overall reduction in dominant fibroid size seems to vary between 
42% - 83%, with the largest reduction in overall fibroid size occurring during the first six 
months and an additional decrease over the next six months (27, 45, 46). Overall uterus 
size reduction post UFE varies from 43% - 58% (27, 45-47).  
In contrast to reduction in fibroid volumes, relief of patient symptoms occurs with much 
higher frequency with a range of 86% - 94% and elimination of abnormal uterine bleeding 
in 88% - 96% of cases (30, 46-48). One such study, a randomized control trial comparing 
UFE to hysterectomy found the success rate of controlling abnormal bleeding after UFE to 
be 88.9% (17) consistent with another previous smaller randomized study (44). 
Pregnancy after UFE 
While UFE does preserve the uterus in contrast to hysterectomy, there is much debate as to 
the safety of UFE in those women desiring future pregnancies. Currently in the literature 
there is only limited data regarding the outcome of pregnancies after UFE. While several 
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studies do report full term pregnancies following UFE, it may be at the cost of higher pre-
partum and post-partum complications (49-51). In a meta-analysis study of previously 
published cases of pregnancy following UFE for symptomatic fibroids, a 32% rate of 
spontaneous abortion was reported compared to a rate of 10-15% in the general population. 
A 22% rate of malpresentation was reported in post-UFE pregnancies vs. 5% in the general 
population, 22% rate of premature delivery vs. 5-10%, a 65% cesarean delivery rate vs. 
22% in the general population, and a 9% rate of postpartum hemorrhage vs. 4-6% in the 
general population (52). The authors report a possibility for the increased malpresentation 
rate due to the presence of residual leiomyomata. In a recent study comparing the outcomes 
of pregnancy post UFE versus laparoscopic myomectomy, the rates of preterm delivery, 
malpresentation, postpartum hemorrhage, and spontaneous abortion were slightly higher in 
pregnancies following UFE, however these increased rates were not statistically significant 
(53). 
Complications of Embolization 
Overall most case reports and studies suggest that UFE has a low complication rate and 
remains safe as an alternative to hysterectomy and myomectomy. A randomized control 
clinical trial comparing UFE to hysterectomy found intra-procedural complication rates to 
be similar between UFE and hysterectomy, 25% versus 20% respectively (44). However 
within the UFE group all events were categorized as minor complications consisting of 
arterial spasm, uterine artery dissection, or gluteal artery perforation. Whereas the 
complications within the hysterectomy group were all categorized as major complications 
with patients either needing transfusion or having had vesical fissure. Post-procedural 
complication rates between the two groups were 72% for UFE and 45% for patients who 
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underwent hysterectomy again with the majority of complications in UFE categorized as 
minor complications versus most of the complications being categorized as moderate and 
major complications in the hysterectomy group. 
A large prospective 400 patient study followed UFE patients over 3 months for all adverse 
events and complications (54). These events and complications were then categorized 
according to the Society of Cardiovascular and Interventional Radiology complication 
classes, A through F, with severity of complications increasing from minor complications, 
class A, to major, severe complications comprising class F. Minor complications listed as 
class A and B occurred in 10.5% of patients with the most common complication listed as 
allergic reaction. Other complications within this category included fibroid passage, 
hematoma, urinary tract infection, femoral nerve injury, urinary retention, deep venous 
thrombosis, and clostridium difficile infection. Class C complications were encountered in 
2.5% of patients. These included four hospitalizations for pain control, four for fibroid 
passage, and two hospitalizations for endometritis. Of the five patients (1.25%) that had 
class D complications, the first patient was diagnosed with a pulmonary embolus, the 
second patient developed bilateral iliac artery thrombosis that was treated with 
thrombolytic therapy. The third patient was hospitalized for a uterine infection 10 weeks 
after embolization secondary to fibroid tissue passage, while the fourth patient had a similar 
infection requiring hysteroscopic removal of the fibroid tissue. The fifth patient had 
extensive bleeding secondary to fibroid passage 4 months following embolization, which 
required a hysterectomy after dilation and curettage failed to control the bleeding. There 
were no reported class E or class F complications within this study and no reported deaths. 
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While not reported in the previously mentioned study, another important, however rare, 
complication includes ovarian failure after UFE. Reported rates of ovarian failure after 
UFE range from 1-2% (43) and are likely secondary to unintended embolization of the 
ovaries via utero-ovarian anastomoses (55). 
Death is also a complication not readily considered given the very low rates of occurrence. 
Currently there are three reported deaths documented in the literature following UFE, two 
of these cases involving pulmonary embolus, and the last death as a result of infection (56, 
57). 
 13
C h a p t e r  2   
STATEMENT OF PURPOSE 
The purpose of this study is to first classify uterine fibroids based on MR image border 
appearance of either the smooth or lobulated variety. Currently no such system exists to 
categorize uterine fibroids based on appearance. The utility of this categorization is to add 
another variable by which to analyze the factors that may play an important role in 
determining fibroids that are more responsive to uterine fibroid embolization (UFE). While 
no good criteria exist for the evaluation of fibroids amenable to treatment by embolization, 
our goal was to evaluate factors of fibroid location, and border appearance to determine if 
any of these criteria could be used as predictive factors for responsiveness to UFE. Using 
existing data classifying outcomes of patients undergoing UFE, we will attempt to correlate 
our categorization of uterine fibroid appearance on MRI to outcomes and MR images post-
embolization. 
Our hypothesis is that a difference exists between the two categories of uterine fibroids 
seen on MRI to the rate of responsiveness following UFE and that fibroids characterized as 
lobulated respond much better to embolization than fibroids characterized as smooth in 
border appearance. While no previous literature exists characterizing fibroids based on 
smooth versus lobulated border criteria, there exists some literature describing variances in 
fibroid signal intensity based on differing pathology. Our hypothesis stems from the 
possibility that fibroids characterized as either smooth or lobulated may exhibit varying 
pathology and thus respond differently to emobolization. 
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Specific Aims 
1. Evaluate pre-embolization MR images of patients with uterine leiomyomas and 
characterize the uterine leiomyoma based on border appearance as well as location. 
2. Evaluate pre-embolization and post-embolization MR images to determine 
outcomes data based on uterine and leiomyoma volume changes. 
3. Correlate the categorization of uterine leiomyoma with outcomes data to determine 
if border characteristics play a role in predicting success in uterine fibroid 
embolization. 
4. Analyze data concerning location of uterine leiomyoma to determine what role if 
any location plays in overall response to uterine fibroid embolization. 
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C h a p t e r  3  
MATERIALS AND METHODS 
This study consists of women evaluated for evidence of uterine fibroids and referred to the 
Yale Interventional Radiology group. Two hundred women were treated with uterine 
fibroid embolization (UFE) for symptomatic fibroids and enrolled in an already HIC 
approved study looking at other outcomes data for embolization. 
MRI images were obtained before and after UAE in 35 women. These images were 
analyzed for uterine and fibroid size changes along with fibroid border characteristics and 
location for a total of 73 fibroids. 
Embolization 
An experience angiographer (MJT) performed bilateral UFE in each patient. A variety of 
embolization agents were used and recorded for each case, with the dominant embolization 
agent being polyvinyl alcohol particles. The institutional review board gave approval for 
the entire study, and each patient gave written informed consent. Patients received pre-
procedural MR images prior to UFE. Patients were seen in clinic and evaluated 6 months 
post-operatively for follow-up. MR images were obtained at this time to observe any 
change in fibroid and uterine size. 
Image Evaluation 
Two readers (TP and SD) independently analyzed MR images for each UFE patient. Pre-
procedural images were used and each reader was given T1 and T2 weighted and 
gadolinium enhanced composite images of the uterus and uterine fibroids. Both readers 
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were blinded to outcome and post-procedural MR images of each case. Within each image, 
T2 fat saturated images were primarily used to ascertain border criteria of each fibroid. 
Fibroids measured to be <3 cm in any diameter were excluded from this study. For each 
fibroid >3cm, the border was described as either smooth or lobulated based on images that 
were defined as standards for each category (see Figure 1). Results were compared and any 
discrepancies in results were shown to an independent third reader (MJT) for analysis and 
categorization. Each fibroid was also evaluated for separate criteria including location and 
size. The size of each fibroid was measured both in the pre-procedural MR image and in 
the follow-up MR image post-procedure. The degree of enhancement in the post-
procedural MR image was also evaluated for each fibroid. The dimensions of the uterus 
were also measure for each pre-procedural MR image and post-procedural MR image. 
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Figure 1. T2 fat saturated, midsagittal MR Images. Images are 
references for determination and categorization of uterine 





The data gathered from each image were placed into an existing database containing dates 
of pre and post – procedural films along with embolization agent used. The volume for 
each fibroid was calculated using the equation for a sphere or prolate ellipse (length * 
width * height * 0.523). The volume of each uterus was also determined using a prolate 
ellipse equation (length * width * height * 0.523) for each pre-procedural MR image and 
post-procedural MR image. The absolute volume change and percentage change for each 
uterus and fibroid was determined with a determination of averages between the fibroids 
categorized as either smooth or lobulated. Using a statistical analysis program (SAS) the 
absolute and percentage volume changes were subjected to an Analysis of Variance 
(ANOVA) test to determine p-values. Also inter-patient variance was determined using a 
fisher t-test. 
Contribution 
My contributions to the project were primarily focused on analyzing and interpreting both 
the pre-operative and post-operative MR images for each patient along with much of the 
statistical analysis performed. Out of the nearly 200 uterine fibroid embolizations (UFE), I 
was present for only a fraction of the cases seen in follow-up clinic. Specifically using an 
already established database containing patient names and dates of embolization along with 
other data points, I analyzed each MR image for every patient listed in the database. I 
categorized each dominant fibroid as to whether the border was either smooth or lobulated 
and merged this information with the existing database. Working with the MR imaging 
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fellow, we were able to measure and mark the location of each fibroid in the pre-operative 
and post-operative images. I entered this data as well into the database and tabulated the 
calculated fibroid and uterine volumes. After all of the imaging data were collected, I 
reformatted the data to be used in a statistical modeling program (SAS) and subsequently 
ran the date through multiple variances of the t-test and ANOVA test. 
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C h a p t e r  4  
RESULTS 
MRI images were obtained before and after UAE in 35 women. These images were 
analyzed for uterine and fibroid size changes along with fibroid border characteristics and 
location for a total of 73 fibroids. 
Volume Changes 
From the analysis of pre-embolization MR images from 35 women, the average uterine 
volume was 656.6 cm3 ± 590.6 cm3 (SD). The average fibroid volume (n= 73) prior to 
embolization was 125.6 cm3 ± 203.9 cm3 (SD). After embolization, the average uterine 
volume was 356.7 cm3 ± 305.2 cm3 (SD). This resulted in an average decrease of 35.7% ± 
24.9% (SD) from pre-embolization uterine volume to post-embolization volume (P < 
0.001). The mean fibroid volume post-embolization was 57.6 cm3 ± 85.8 cm3 (SD), 
resulting in an average decrease of 48.1% ± 28.6 % (SD) from pre- to post-embolization 
volume (P < 0.001). The mean elapsed time between pre-embolization and post-
embolization MR images was approximately 38 weeks and 5 days. 
Prognostic Features 
Two categories of prognostic features were analyzed, border appearance and location. 
Border appearance was described as either smooth or lobulated. Approximately 29.3% of 
fibroids were lobulated (n= 22) with an average volume of 237.5 cm3 ± 203.9 cm3 (SD) 
pre-embolization and an average volume of 129.4 cm3 ± 101.2 cm3 (SD) post-
embolization. Fibroids categorized as smooth comprised 70.7% (n= 53) of the total fibroids 
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with an average volume of 83.4 cm3 ± 189.1 cm3 (SD) pre-embolization and an average 
volume of 30.5 cm3 ± 70.0 cm3 (SD) post-embolization. The average volume change in 
lobular fibroids from pre-embolization volume to post-embolization volume was 108.1 
cm3 ± 143.0 cm3 (SD) resulting in a reduction of 40.6% ± 23.1% (SD). In fibroids 
characterized as smooth, the average volume change from pre-embolization to post-
embolization was 52.9 cm3 ± 164.9 cm3 (SD) resulting in a reduction of 50.9% ± 30.2% 
(SD). 


















Figure 2. Graph shows a comparison of mean reduction in fibroid 
volume before and after embolization between lobulated and 
smooth fibroids. Error bars indicate 95% confidence intervals for 
each group. 
The calculated confidence interval for the mean change in volume between lobulated and 
smooth fibroids is [-25.1, 4.6, SEM 7.5, Df 71]. Since this interval includes zero, the 
possibility that both mean volume changes may be equal exists, and we cannot conclude 
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that there is statistical difference between the mean volume changes in both groups. Single 
factor ANOVA demonstrated no appreciable difference of mean volume change between 
the two groups (F [1,71]= 1.88, Fcrit= 3.98, p= 0.17). However if we define failure of 
embolization as no reduction or increase of fibroid volume from pre-embolization to post-
embolization, there was a single failure within the lobulated fibroids for a failure rate of 
5%. Within fibroids categorized as smooth, there were a total of five failures for a failure 
rate of 9.4%. Single factor ANOVA demonstrated some difference between the two groups 
when looking at failure rate, however with low statistical power (F [1, 71]= 0.37, Fcrit= 
3.98, p= 0.26). 

















Figure 3. Graph illustrates a comparison of pre-embolization and 
post-embolization fibroid volume reduction in fibroids between 
smooth and lobulated fibroids. Box plots show median (middle line 
of box), first quartile (bottom line of box), third quartile (top line of 
box), minimum values (lower whisker), and maximum values (upper 
whisker). 
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Similar results were obtained when looking at location as a prognostic indicator. While 
there was some difference between the groups, there was little statistical power to indicate 
with certainty that location is a prognostic factor in determining outcome after 
embolization. Approximately 64.4% of fibroids were intramural (n= 47), 12.3% 
submucosal (n=  9), and 23.3% subserosal (n= 17). The mean pre-embolization volume for 
intramural fibroids was 155.1 cm3 ± 218.7 cm3 (SD) with a mean post-embolization 
volume of 65.2 cm3 ± 86.0 cm3 (SD). The mean pre-embolization volume for submucosal 
fibroids was 127.2 cm3 ± 276.5 cm3 (SD) with a mean post-embolization volume of 71.6 
cm3 ± 138.7 cm3 (SD). The mean pre-embolization volume for subserosal fibroids was 
43.3 cm3 ± 41.0 cm3 (SD) with a mean post-embolization volume of 29.1 cm3 ± 32.8 cm3 
(SD). The average change in volume from pre-embolization volume to post-embolization 
volume in each of the groups was 89.8 cm3 ± 186.2 cm3 (SD), 55.6 cm3 ± 148.5 cm3 
(SD), 14.3 cm3 ± 12.0 cm3 (SD) respectively for intramural, submucosal, and subserosal 
fibroids for a reduction in volume of 51.6% ± 30.2% (SD) in intramural fibroids, 43.9% ± 
29.4% (SD) in submucosal fibroids, and 40.6% ± 22.9% (SD) in subserosal fibroids. Single 
factor ANOVA demonstrated no appreciable difference of mean volume change between 
the three groups (F [2,70]= 1.04, Fcrit= 3.13, p > 0.2). 
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Figure 4. Graph illustrates a comparison of pre-embolization and 
post-embolization fibroid volume reduction in fibroids of different 
locations. Box plots show median (middle line of box), first quartile 
(bottom line of box), third quartile (top line of box), minimum 
values (lower whisker), and maximum values (upper whisker). 
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C h a p t e r  5  
DISCUSSION 
Discussion 
Findings from this study do not clearly demonstrate a significant difference in volume 
reduction between fibroids categorized as either lobulated or smooth on MR imaging. 
While some minor differences are noted, the low statistical power does not allow us to 
draw a distinct conclusion. Similarly, findings from this study do not suggest a significant 
difference in volume reduction of fibroids post-embolization based upon fibroid location. 
Our study does suggest some minor difference when looking at overall embolization failure 
rate rather than volume changes between smooth and lobulated fibroids, albeit again with 
low statistical power. 
Uterine volumes 
Clearly the relative change in uterine volume relative to fibroid type is not of statistical 
significance. Uterine volume as a measurement of embolization success is an inaccurate 
predictor of overall success given that uterine volume changes in accordance to a variety of 
factors. When measuring uterine volumes post-embolization, relative changes in fibroids 
seen on the pre-procedural MR image are measured along with fibroids that may not have 
been seen at the time of the initial MR image that have since increased in size. Thus overall 
uterine volume is not an accurate predictor of embolization success and although useful 
cannot be used to ascertain predictive factors that determine outcome. The usefulness of 
uterine volume changes in determining the differences between smooth and lobulated 
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fibroids is also confounded by the fact that in some of the patients, multiple fibroids of both 
varieties were present, rendering the uterine volume change useless in those patients. 
Fibroid volumes 
While uterine volume change is not an accurate assessment of success following 
embolization, individual fibroid volume changes are an accurate measurement of response 
following embolization. Previous studies investigating predictive factors correlating to 
embolization success have used a variety of findings to measure success including 
ultrasonography and improvement in physical symptoms. MR provides an improved 
accuracy over ultrasonography and a much simpler measure of success over improvement 
in physical symptoms. The value of improvement in clinical symptoms is certainly 
important following embolization, however there is such variability in assessing such 
criteria that it becomes very difficult to ascertain a true measure of success given the 
subjective nature of obtaining patient history. Several studies have validated the use of MR 
characteristics as a measurement of success following embolization (58).  
There was a significant reduction in mean uterine fibroid volumes in our study. This result 
is consistent with the 45%-65% range of mean uterine fibroid volume reduction reported in 
other studies (33). Our results showed that there was little difference in the overall 
reduction of fibroid volumes between smooth and lobulated fibroids, with little statistical 
power suggesting a strong difference in response. It is unclear why on average fibroids of 
the lobulated variety were nearly three times the size of the smooth variety. Not all large 
fibroids were of the lobulated variety and not all small fibroids were of the smooth variety. 
Whether this size difference confounds our data regarding the overall percentage change in 
fibroids post-embolization is also unclear. There has been some speculation that larger 
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uterine volumes and larger fibroid volumes may exhibit varying responses to embolization 
secondary to embolization particle distribution (59). Also a greater number of embolization 
particles may be required for larger fibroids, rather than current protocols that do not titrate 
embolization particles based on size of uterus or fibroids.  
Predictive Factors 
Despite the relative lack of difference in fibroid volume change between the two groups, 
when looking at failure defined as an increase in fibroid size after embolization there was a 
trend towards a difference between the two groups. Only one fibroid within the lobulated 
category increased in size post-embolization representing a 5% failure rate. This is in 
contrast to the fibroids categorized as smooth which had a near 10% failure rate, with five 
fibroids showing an increase in size after embolization. It is hard to draw a definite 
conclusion based on this result in the absence of correlation based on overall mean fibroid 
volume change between the two groups, however it does suggest some fundamental 
difference between fibroids classified as either smooth or lobulated. Whether this 
difference extends to the level of pathology is unclear and certainly warrants further 
investigation. Previous studies suggest different cellular pathology for fibroids exhibiting 
varying signal intensity levels on MR, with high signal intensity fibroids composed of 
compact smooth muscle cells compared to fibroids exhibiting decreased signal intensity 
due to uniform smooth muscle cells with various amounts of intervening collagen (60, 61). 
Perhaps lobulated fibroids exhibit similar disparities on pathology compared to fibroids 
with a smooth border appearance, to date there exists no literature mentioning any 
characteristics of either smooth or lobulated fibroids. 
 28
While the main focus of this study was the categorization of fibroids based on MR image 
appearance, the data allow for other factors to be independently analyzed. The location and 
type of each fibroid was noted for use as a possible predictor of outcome post-
embolization. While not thoroughly characterized, some studies have concluded that 
submucosal fibroids have a strong correlation to positive outcomes as compared to 
intramural and subserosal fibroids (59). Our study found no real correlation between 
location of fibroid and change in fibroid volume after embolization. 
Limitations of the study 
While every step was taken to ensure that the data gathered were accurate and not 
misrepresented, every study has certain limitations that must be considered when drawing a 
conclusion regarding data presented within the study. Certainly as is true for many studies, 
sample size plays a large role in the power of a study. In our case, while the sample size is 
quite large, there is still not enough data regarding the non-responders to embolization. 
Given that success rates of embolization in regards to overall reduction of fibroid size vary 
from 42% to 83% (27, 45, 46), and in our study roughly 90%, the total sample size of cases 
in which fibroids did not respond to embolization is very low. Naturally, increasing the 
sample size and thus increasing the number of cases in which failure occurred would add 
statistical power to the study to analyze factors that play a role in determining non-
responders to embolization. 
Several other potential sources of error play a role in determining the conclusions that can 
be drawn from this study. One large source of error comes from the subjective nature of 
determining the characteristic of the fibroid border. Since categorizing fibroids as either 
lobulated or smooth is not a readily quantifiable measurement, this introduces a source 
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potential error. While an attempt to minimize this error was made by having two 
independent readers categorize each fibroid and a third reader to rectify any discrepancy, 
this cannot be ruled out as a potential source of error. Another limitation of this study is the 
inability to factor many of the other variables that may have played a role in the outcomes 
of both fibroid and uterine volumes after embolization. These factors include the relative 
location of each fibroid as well as the presence of adenomyosis. As mentioned the role of 
embolization in patients with adenomyosis is unclear. Several studies report no 
improvement in patients with adenomyosis (33, 34), whereas a single recent study does 
report improvement after embolization (35). It is unclear what role adenomyosis plays in 
the reduction of individual fibroid and uterine size post-embolization. In our study we were 
unable to distinguish between patients with adenomyosis from those without adenomyosis. 
Another factor that was not accounted for in this study was the choice of embolization 
agent used for each patient. While the dominant embolization agent was polyvinyl alcohol 
particles, the choice of embolization agent and resultant outcome based on agent used was 
not determined. However based upon the single patient variance studies, the variability of 
embolization agent used would not play a role. 
Lastly, while the majority of fibroids decrease in size the greatest over the first 6 months 
post-embolization (46), not all fibroids decrease at the same rate. Ideally follow-up images 
would be obtained at identical times post-embolization for each patient and at multiple time 
points, however in reality this is not technically feasible given the variability in availability 
of imaging resources and the incapacity to obtain multiple MR images for a large patient 
sample. In our study there was some variability between each patient in the length of time 
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that images were obtained post-embolization. This variability could have played some role 
in the overall measurement of reduction in both fibroid and uterine volumes. 
Despite the potential limitations of this study, the data provide some interesting conclusions 
in the response of fibroids to embolization and warrant further investigation into the 
potential differences that contribute to the appearance on MR imaging of fibroids as either 
smooth or lobulated and what differences, if any, there are in response to embolization. 
Conclusion 
Currently uterine fibroid embolization (UFE) is a viable treatment option for women 
experiencing symptomatic uterine fibroids not wanting to undergo hysterectomy. While the 
overall success rate of UFE is very good, there exist a small percentage of women who do 
not benefit from UFE. However, to date no reliable criteria exist regarding the prediction of 
outcomes amongst women undergoing UAE for uterine fibroids. Size of fibroids has been 
in some studies implicated as a predictive factor (43, 47), however this finding has not been 
consistent throughout studies looking at predictive factors (30, 58). A predictive factor that 
would classify uterine leiomyomas as either likely responders or non-responders would be 
of great use in determining proper pre-embolization candidates and likely increase the 
overall response rate in UAE as well as overall patient satisfaction. 
We introduced a novel characteristic by which to classify uterine fibroids based upon 
border appearance on MR imaging in the hopes of elucidating what role, if any, border 
appearance has on outcomes following embolization. Although we were not able to show a 
significant difference in volume reduction between those fibroids categorized as either 
lobulated or smooth, we were able to note an albeit small difference in embolization failure 
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rates between smooth and lobulated fibroids. Further, our analysis did not reveal any 
difference based upon fibroid location in overall volume reduction after embolization. 
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